I-Mab Biopharma (IMAB) Reports China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors

Go back to I-Mab Biopharma (IMAB) Reports China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
(NASDAQ: IMAB) Delayed: 63.22 -0.38 (0.6%)
Previous Close $63.60    52 Week High
Open $65.00    52 Week Low
Day High $65.00    P/E N/A 
Day Low $62.50    EPS
Volume 224,044